statins

Ake Hjalmarson Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 AKE HJAL

Judith Hochman Timothy Gardner Girish Mood Marc Cohen Late Opening of Total Occlusion: No Benefit from PCI for Patients with STEMI REFERENCE: LBCT II News Conference November 14th 2006 JUDITH HOCHMAN,

Gilles Montalescot Freek Verheugt Angioplasty: Four-Continent RIVIERA Study Identifies “Real World” Modifiable Factors Which Affect Outcome REFERENCE: Abstract 3413, “Hot Line II&rdq

Annual Meeting of the American College of Cardiology March 11-14, 2006, Atlanta: Atheroma Reversal, Statins for Acute Coronary Syndromes, Targeting Dual Antiplatelet Therapy, Clopidogrel and Drug Elut

Anthony Bavry, The Cleveland ClinIc, OH American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta. Abstract Number: 821-5 All cause mortality can be reduced by 25 per cent if

Germano Di Sciascio, Campus Biomedico University of Rome American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta The anti-inflammatory action of statins may be causing yet

Steven Nissen, Cleveland Clinic, Cleveland, Ohio American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta Among patients whose atheroma had been measured by a catheter ultra

Donald Redelmeier, University of Toronto Abstract: Lancet 2006; 367:413 Treatment with the lipid lowering agents statins reduced the incidence of sepsis among a large group of patients with cardiovasc

John McMurray The VALIANT trial compared ACE-inhibitor, ARB and a combination of the two in high-risk post-MI patients, and found there may be an interaction between them and statins. John McMurray fr

In addition to lipid levels, statins are known to have anti-inflammatory, anti-thrombotic and immunomodulatory effects which could help explain their impact on cardiovascular outcomes. But do these pl